Precision BioSciences (NASDAQ:DTIL) saw its stock rise 5% following the announcement that the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to its PBGENE-DMD therapy for ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 “In 2024, Precision is ...

Precision BioSciences shares are trading higher Tuesday after the company announced a licensing agreement with TG Therapeutics, Inc. Precision will receive $17.5 million in upfront and near-term ...

- Company to expand its Phase 1 ELIMINATE-B study to the U.S., joining world-class clinical sites in Moldova, Hong Kong, and New Zealand where strong clinical execution is currently underway ...

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...

Investing.com -- Precision BioSciences (NASDAQ: DTIL) stock rose 5% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PBGENE-DMD ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.